Show simple item record

dc.contributor.authorLegros, D
dc.contributor.authorOllivier, G
dc.contributor.authorGastellu-Etchegorry, M
dc.contributor.authorPaquet, C
dc.contributor.authorBurri, C
dc.contributor.authorJannin, J
dc.contributor.authorBüscher, P
dc.date.accessioned2008-02-14T11:39:47Z
dc.date.available2008-02-14T11:39:47Z
dc.date.issued2002-07
dc.identifier.citationTreatment of human African trypanosomiasis--present situation and needs for research and development. 2002, 2 (7):437-40notLancet Infect Disen
dc.identifier.issn1473-3099
dc.identifier.pmid12127356
dc.identifier.urihttp://hdl.handle.net/10144/18268
dc.description.abstractHuman African trypanosomiasis re-emerged in the 1980s. However, little progress has been made in the treatment of this disease over the past decades. The first-line treatment for second-stage cases is melarsoprol, a toxic drug in use since 1949. High therapeutic failure rates have been reported recently in several foci. The alternative, eflornithine, is better tolerated but difficult to administer. A third drug, nifurtimox, is a cheap, orally administered drug not yet fully validated for use in human African trypanosomiasis. No new drugs for second-stage cases are expected in the near future. Because of resistance to and limited number of current treatments, there may soon be no effective drugs available to treat trypanosomiasis patients, especially second-stage cases. Additional research and development efforts must be made for the development of new compounds, including: testing combinations of current trypanocidal drugs, completing the clinical development of nifurtimox and registering it for trypanosomiasis, completing the clinical development of an oral form of eflornithine, pursuing the development of DB 289 and its derivatives, and advancing the pre-clinical development of megazol, eventually engaging firmly in its clinical development. Partners from the public and private sector are already engaged in joint initiatives to maintain the production of current drugs. This network should go further and be responsible for assigning selected teams to urgently needed research projects with funds provided by industry and governments. At the same time, on a long term basis, ambitious research programmes for new compounds must be supported to ensure the sustainable development of new drugs.
dc.language.isoenen
dc.publisherElsevier
dc.relation.urlhttp://www.thelancet.com/journals/laninf
dc.rightsReproduced on this site with permission of Elsevier Ltd. Please see www.TheLancet.com/journals/laninf for further relevant comment.en
dc.subject.meshAfrica South of the Saharaen
dc.subject.meshAnimalsen
dc.subject.meshBenzamidinesen
dc.subject.meshDrug Therapy, Combinationen
dc.subject.meshEflornithineen
dc.subject.meshHumansen
dc.subject.meshMelarsoprolen
dc.subject.meshNifurtimoxen
dc.subject.meshThiadiazolesen
dc.subject.meshTrypanocidal Agentsen
dc.subject.meshTrypanosoma brucei gambienseen
dc.subject.meshTrypanosoma brucei rhodesienseen
dc.subject.meshTrypanosomiasis, Africanen
dc.titleTreatment of human African trypanosomiasis--present situation and needs for research and development.en
dc.contributor.departmentEpicentre, Paris, France. dlegros@epicentre.msf.orgen
dc.identifier.journalLancet Infectious Diseasesen
refterms.dateFOA2019-03-04T09:19:37Z
html.description.abstractHuman African trypanosomiasis re-emerged in the 1980s. However, little progress has been made in the treatment of this disease over the past decades. The first-line treatment for second-stage cases is melarsoprol, a toxic drug in use since 1949. High therapeutic failure rates have been reported recently in several foci. The alternative, eflornithine, is better tolerated but difficult to administer. A third drug, nifurtimox, is a cheap, orally administered drug not yet fully validated for use in human African trypanosomiasis. No new drugs for second-stage cases are expected in the near future. Because of resistance to and limited number of current treatments, there may soon be no effective drugs available to treat trypanosomiasis patients, especially second-stage cases. Additional research and development efforts must be made for the development of new compounds, including: testing combinations of current trypanocidal drugs, completing the clinical development of nifurtimox and registering it for trypanosomiasis, completing the clinical development of an oral form of eflornithine, pursuing the development of DB 289 and its derivatives, and advancing the pre-clinical development of megazol, eventually engaging firmly in its clinical development. Partners from the public and private sector are already engaged in joint initiatives to maintain the production of current drugs. This network should go further and be responsible for assigning selected teams to urgently needed research projects with funds provided by industry and governments. At the same time, on a long term basis, ambitious research programmes for new compounds must be supported to ensure the sustainable development of new drugs.


Files in this item

Thumbnail
Name:
lancet legros HAT.pdf
Size:
448.3Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record